Abstract

We attempt to study the therapeutic effect of pidotimod assisted fluticasone propionate in children with asthma and the improvement of their immune function. We selected 93 asthmatic children admitted to the hospital from May 2021 to December 2022 for the trial. Divided them into experimental group (46 cases) and reference group (47 cases) by computerized numbered random number table. All children received conventional therapy; the experimental group was treated with fluticasone propionate, while the reference group was treated with pidotimod in addition to the experimental group. All children received 90 d treatment, compared both groups on the treatment effect, immune function and peripheral blood levels of interferon regulatory factor 1 and signal transducer-activated transcription factor-1 and the incidence of adverse effects before and after treatment. Experimental group possessed shorter disappearance time of all clinical symptoms shorter than reference group (all p<0.05). After 90 d treatment, the cluster of differentiation 3+, cluster of differentiation 4+ and cluster of differentiation 4+/cluster of differentiation 8+ in the experimental group were (66.91±12.30) %, (45.23±4.56) % and (1.82±0.52) %, respectively, which were all higher than those in the reference group (61.45±11.73) %, (42.82±4.19) % and (1.54±0.40) %, while the cluster of differentiation 8+ was ( (28.37±2.42) %, which was lower than (30.06±2.75) % in the reference group (all p<0.05). After 90 d treatment, experimental group had lower interferon regulatory factor 1 and signal transducer-activated transcription factor-1 levels than reference group (both p<0.05). The incidence of nausea and vomiting, arthralgia, rash and dizziness were not significantly compared between both groups (all p>0.05). Pidotimod adjuvant to fluticasone propionate in children with asthma is effective and can improve their immune function and interferon regulatory factor 1 and signal transducer-activated transcription factor-1 expression levels without increasing the risk of adverse reactions, so it is worth promoting.